Barcelona, 18 September 2014 – Officially celebrated during yesterday´s award ceremony of the Spanish Association Against Cancer (AECC), presided by…
news
Latest research at VHIO confirms 4 subgroups of HER2+ breast cancer with different molecular characteristics The diagnostic test for these…
Latest research from the Vall d’Hebron Institute of Oncology (VHIO) in Barcelona, recently published in the prestigious journal Cancer Discovery,…
Latest research at VHIO validates Myc inhibition as an effective therapeutic strategy against brain tumors The Myc protein also plays…
Aimed at exploring all aspects of the translational research continuum, from early detection through treatment to survivorship, this special 5-day…
Inés Gasén was diagnosed with breast cancer during her pregnancy – not only naturally provoking fear and uncertainty for her…
Taking place on Monday 08 September 2014, beginning with a Welcome coffee at 14:15 – 14:30, followed by the main…
ESMO welcomes the adoption of the Clinical Trials Regulation by the European Union Source: The European Society for Medical Oncology…
VHIO is delighted to announce that Charles M. Perou, May Goldman Shaw Distinguished Professor of Molecular Oncology, professor of genetics,…
Findings presented today at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), May 30 – June 03, Chicago IL, USA, reveal that HER2+ breast cancer patients expressing high protein levels respond better to targeted therapy and survive longer.
